AU6137399A - Method of determining and reducing the risk of bph-related urologic events - Google Patents

Method of determining and reducing the risk of bph-related urologic events

Info

Publication number
AU6137399A
AU6137399A AU61373/99A AU6137399A AU6137399A AU 6137399 A AU6137399 A AU 6137399A AU 61373/99 A AU61373/99 A AU 61373/99A AU 6137399 A AU6137399 A AU 6137399A AU 6137399 A AU6137399 A AU 6137399A
Authority
AU
Australia
Prior art keywords
urologic
bph
events
risk
determining
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU61373/99A
Inventor
Elizabeth Stoner
Joanne Waldstreicher
Daniel Z. Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of AU6137399A publication Critical patent/AU6137399A/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/342—Prostate diseases, e.g. BPH, prostatitis
AU61373/99A 1998-09-09 1999-09-03 Method of determining and reducing the risk of bph-related urologic events Abandoned AU6137399A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9962098P 1998-09-09 1998-09-09
US60099620 1998-09-09
PCT/US1999/020451 WO2000013509A1 (en) 1998-09-09 1999-09-03 Method of determining and reducing the risk of bph-related urologic events

Publications (1)

Publication Number Publication Date
AU6137399A true AU6137399A (en) 2000-03-27

Family

ID=22275869

Family Applications (1)

Application Number Title Priority Date Filing Date
AU61373/99A Abandoned AU6137399A (en) 1998-09-09 1999-09-03 Method of determining and reducing the risk of bph-related urologic events

Country Status (2)

Country Link
AU (1) AU6137399A (en)
WO (1) WO2000013509A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070298028A1 (en) * 2004-02-19 2007-12-27 Bayer Healthcare Ag Diagnostics and Therapeutics for Diseases Associated With Kallikrein 3 (Klk3)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1275594B1 (en) * 1995-07-21 1997-08-06 Pharmacia S P A Ora Pharmacia EPIMERS OF (22RS) -N- (1,1,1-TRIFLUORO-2-PHENYLPROP-2-IL) -3-BONE -4-AZA-5ALFA-ANDROST-1-ENE-17BETA-CARBOSSAMIDE
AU707324B2 (en) * 1995-09-15 1999-07-08 Merck & Co., Inc. 4-azasteroids for treatment of hyperandrogenic conditions
CA2308070A1 (en) * 1997-10-28 1999-05-06 Merck & Co., Inc. Prevention of precipitated acute urinary retention

Also Published As

Publication number Publication date
WO2000013509A1 (en) 2000-03-16

Similar Documents

Publication Publication Date Title
AU9247398A (en) Liquid-cristal display and the method of its fabrication
AU2099799A (en) Optoelectronic assembly and method of making the same
AU5382499A (en) Self-evolving database and method of using same
AU6886598A (en) Hosel construction and method of making the same
AU9216398A (en) Fastener assembly and method of making the same
AU6564398A (en) Wagering system and method of wagering
AU4208799A (en) Interleukins-21 and 22
AU5643698A (en) Common rail and method of manufacturing the same
AU2238697A (en) Display arrangement and method
AU5643798A (en) Common rail and method of manufacturing the same
AU1516297A (en) Power-saving method and circuit
AP2001002080A0 (en) Pilveriser and method of pulverising
AU2840995A (en) Vibration-generating-motor mounting structure and its mounting method
AU3606799A (en) Method and arrangement for measuring the structures of an object
AU3492997A (en) Soi-transistor circuitry employing soi-transistors and method of manufacture thereof
AU2762699A (en) Micro-fastening system and method of manufacture
EP0860883A4 (en) Transistor and method of manufacturing the same
SG71064A1 (en) Package and method of manufacture of the same
AU6270799A (en) Firestarter and method of making same
AU4567999A (en) Distributed amplifier and method therefor
AU1668100A (en) Improved fixing device and method
AU5779798A (en) Culture unit and method of manufacturing the same
AU6640498A (en) Package and method of making the same
AU6917198A (en) Loudspeaker and method of manufacturing the same
AU8460898A (en) Projecting indicator and method of manufacturing the same

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase